Psyched Wellness (PSYC) AI Stock Analysis

• Market Cap: C$5.78M
• Dividend Yield: N/A
• Average Volume (3M): 132.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 97.11%
• EPS Growth: 5.85%
• Country: CA
• Employees: 1,800
• Sector: Healthcare
• Sector Strength: 41
• Industry: Packaged Foods
• EPS (TTM): -0.02
• Shares Outstanding: 288,816,830
• 10 Day Avg. Volume: 195,387
• 30 Day Avg. Volume: 132,084
• PEG Ratio: -0.09
• Price to Book (P/B): 0.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Psyched Wellness presents a complex investment case. While the company shows promising revenue growth and a stable equity position, its ongoing profitability challenges and negative valuation metrics weigh heavily on its overall score. Technical analysis suggests a bearish trend, further compounded by valuation concerns. However, strategic corporate events provide a glimpse of potential future upside, reflecting a modestly positive outlook.

Psyched Wellness Business Overview & Revenue Model

Company Description

Psyched Wellness (PSYC) is a Canadian-based biotechnology company focused on the development and commercialization of medicinal mushroom products. Operating within the health and wellness sector, the company is dedicated to harnessing the therapeutic properties of psychedelic compounds found in mushrooms, particularly Amanita Muscaria, to create innovative products aimed at enhancing mental and physical well-being. Psyched Wellness is committed to rigorous scientific research to ensure the safety and efficacy of its products, which include tinctures, capsules, and other formulations designed to support stress relief, mood enhancement, and improved sleep quality.

How the Company Makes Money

Psyched Wellness generates revenue primarily through the sale of its proprietary mushroom-based health supplements and wellness products. These products are marketed directly to consumers through online platforms and select retail partners. The company may also engage in strategic partnerships and collaborations within the biotechnology and healthcare sectors to expand its market reach and product offerings. Additional revenue streams could potentially include licensing agreements for their proprietary formulations and intellectual property, as well as potential future offerings in the form of wellness services or experiences. However, specific financial data or detailed revenue breakdowns are not publicly disclosed.

Psyched Wellness Financial Statement Overview

Summary

Psyched Wellness shows strong revenue growth, yet it faces persistent challenges with profitability and cash flow. While the company boasts a solid equity position and no debt, negative profit margins and cash flow deficits highlight the need for strategic improvements.

Income Statement

Psyched Wellness has shown strong revenue growth, increasing from CAD 14,274 in 2022 to CAD 623,156 in 2024, marking a significant growth trajectory. However, the company continues to operate at a net loss with a negative net profit margin of -683% for 2024, and its EBIT and EBITDA margins are also negative, indicating ongoing challenges in achieving profitability.

Balance Sheet

The balance sheet shows a solid equity position with a debt-to-equity ratio of 0, highlighting the company's reliance on equity rather than debt. However, the return on equity remains negative at -57.3%, reflecting the company's struggles with profitability. The equity ratio is robust at 94.3%, indicating financial stability.

Cash Flow

The company has maintained a stable cash position with significant cash reserves of CAD 6,357,977 in 2024. However, the free cash flow remains negative, and the operating cash flow to net income ratio is less than ideal, indicating ongoing cash flow challenges despite successful financing activities.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
623.16K	321.10K	14.27K	0.00	0.00
	Gross Profit
241.89K	155.71K	7.54K	0.00	-10.00K
	EBIT
-4.52M	-3.33M	-3.87M	-4.48M	-2.15M
	EBITDA
-4.52M	-3.32M	-4.01M	-65.14K	-2.06M
	Net Income Common Stockholders
-4.26M	-3.43M	-4.73M	-4.50M	-2.08M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.36M	6.13M	2.57M	5.53M	2.06M
	Total Assets
7.89M	7.34M	3.31M	6.38M	3.21M
	Total Debt
0.00	0.00	0.00	0.00	0.00
	Net Debt
-6.36M	-6.13M	-2.57M	-5.53M	-2.06M
	Total Liabilities
449.33K	303.56K	198.07K	178.15K	34.85K
	Stockholders Equity
7.44M	7.03M	3.11M	6.20M	3.18M
Cash Flow		Free Cash Flow
-3.11M	-3.11M	-3.18M	-3.04M	-2.31M
	Operating Cash Flow
-3.10M	-3.03M	-3.09M	-3.01M	-2.31M
	Investing Cash Flow
-2.78K	-44.84K	126.99K	-28.58K	0.00
	Financing Cash Flow
3.39M	6.64M	0.00	6.51M	4.37M

Psyched Wellness Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PSYC, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.03 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:PSYC.

Psyched Wellness Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.82%	16.45%	-0.47%
TRIP	51 Neutral	$12.03M	―	-30.44%	―	13.57%	-14.29%
PSYC	44 Neutral	C$5.78M	―	-68.64%	―	97.11%	5.85%
CYBN	37 Underperform	$1.97M	―	-58.79%	―	―	51.37%

Psyched Wellness Corporate Events

Psyched Wellness Completes Pilot Run for New Dietary Supplement

Psyched Wellness Ltd. announced the completion of an initial pilot run for a new dietary supplement shot through its US subsidiary, AME Wellness Inc. The pilot aims to test the product with a select group of consumers and gather feedback on various aspects, including taste and marketing data. The company is also preparing its fulfillment capabilities ahead of the product’s official launch, indicating a strategic move to expand its market presence and partnerships.

Psyched Wellness Announces Genotoxicity Study and Strategic Developments

Psyched Wellness has announced a series of corporate updates, including the initiation of a Genotoxicity Study on its proprietary Amanita Muscaria Extract (AME-1) to ensure its safety as a dietary supplement. The company has also completed a production run for its products, AME-1 and Calm, to meet online and retail demand, and is working on securing a long-term manufacturing agreement. Strategic partnerships, such as with Zerkalo LLC, are progressing in the development of new dietary supplements, and the company is expanding its route-to-market partnerships nationwide.